The Alliance for Artificial Intelligence in Healthcare (AAIH)’s Post

🧠 Latest 🇺🇸🇪🇺 deals in life sciences and healthcare...👇 🤍  Cardiology group Cardiovascular Associates of America, backed by Webster Equity Partners, partners with athenahealth to provide its cardiologists with advanced cloud-based tools. 🔬  Syncona Limited merges Freeline Therapeutics and SwanBio Therapeutics to form Spur Therapeutics, backed by £40m in additional financing from Syncona. 🌍  Sidekick Health, an Iceland-based digital health company, acquires PINK!, a Germany-based digital health firm specializing in cancer support and women’s health. 🏥  Great Point Partners (GPP) acquires Lyocontract GmbH, a Germany-based CDMO specializing in aseptic liquid filling, lyophilization, and packaging services. 🇨🇦  Neighbourly Pharmacy Inc., owned by Persistence Capital Partners, expands its Canadian presence with the acquisition of six pharmacies across Canada. 💸  INSIGHTEC, a healthcare firm specializing in focused ultrasound, raises $150m in equity financing, led by Fidelity Management And Research Company. 🌱  Bay Tree Private Equity LLP supports ABL Health's management buyout, aiming to enhance community-driven health services and reduce inequalities. ⚡  RevOpsis Therapeutics teams up with Kemwell Biopharma to speed up development of RO-104, a treatment for neovascular age-related macular degeneration. 💊  Sanofi and Belharra partner in a $700 million deal to advance small molecule therapies for immunological diseases, leveraging Belharra’s chemoproteomic platform for drug discovery. 🧬  Ascidian Therapeutics partners with Roche to develop RNA therapies for neurological diseases, potentially earning up to $1.8 billion in milestone payments. 🏭  Unither Pharmaceuticals invests $106 million to modernize its facility, with expansion efforts expected to create 180 jobs by 2029. 💰  Day One Biopharmaceuticals acquires MTX-13 from MabCare for $55m upfront to develop and commercialize DAY301, an ADC targeting PTK7. 🔗  Suven Pharmaceuticals has agreed to acquire a 67.5% stake in SAPALA ORGANICS PVT LTD, expanding its CDMO business into oligonucleotide technology. 🩺  AbbVie teams with FutureGen Laboratories to develop FG-M701 for IBD, offering potential $1.56B in milestones. ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT is connecting senior industry experts, ex-payors and KOLs with consultants and investors in Life Sciences and Healthcare for expert calls and advisory services. Like my content? Join 13k+ followers by clicking my name + follow + 🔔

👨🔬 This weeks biggest news in the Life Science & Healthcare Industries ⬇ 🏛 US judge denies initial attempt by Novartis to block generic Entresto launch 💉 Bavarian Nordic outlays 215,000 mpox vaccine dose supply to African countries 🏥 Eli Lilly and Company inaugurates R&D facility in Boston, US 🤝 Medtronic announces partnership with Abbott to improve faltering diabetes care segment ✂ Evotec slashes workforce by 400 people in “difficult market” 📉 Actinogen Medical stocks plummet after Phase IIa depression trial failure 🧠 UAE approves BioArctic and Eisai Co., Ltd.’s Leqembi for Alzheimer’s disease 👨⚕️ Oracle Health’s EHR enhances cancer treatment at Alfred Health 💉 Pfizer touts positive topline data for RSV vaccine Abrysvo 📈 Spectral Medical Inc.’s revenue up 54% as company eyes Tigris trial completion 💵 Halda Therapeutics secures $126m of funding to begin trials of cancer therapies 📅 Autonomix Medical targets first half of 2025 for topline data from proof-of-concept study ✅ SOPHiA GENETICS secures CE mark for DDM analytics platform under EU’s IVDR ⌚ Clario and Mobilise-D to integrate DMOs with wearable sensor technology for trials 🤝 Baxter International Inc. signs over kidney care arm to investment firm The Carlyle Group in $3.5bn deal 🤖 Stereotaxis’ endovascular robotic system wins EU clearance 🤝 Stryker acquires smart hospital tech provider care.ai 💊 Blue Earth Therapeutics and Seibersdorf Labor GmbH expand radiopharmaceutical manufacture deal 🏥 Apollo Hospitals reports 83% YoY growth in PAT for Q1 FY25 🤝Isala hospital and Philips renew collaboration to enhance healthcare delivery 👍 Gilead Sciences’s PBC therapy Livdelzi bags accelerated approval 🆕 Otsuka Pharmaceutical Co., Ltd. and Click Therapeutics, Inc. officially launch MDD digital therapeutic You can keep up to date with all the top stories in the life science industry by following GlobalData Plc's healthcare industry news sites 💊 Pharmaceutical-Technology, ⚕ Medical Device Network, 💉 Clinical Trials Arena and 🏥 Hospital Management 🎯 If you would like to learn about our award winning content &marketing solution from GlobalData Marketing Solutions then please feel free to drop me a DM or send me an email - josh.jones@globaldata.com📧 #pharma #medicaldevice #medtech #clinicaltrials #biopharma #biotech #hospitals #diabetes #mpox #oncology #IVDR #wearables #medicalrobotics #radiopharmaceuticals #healthcare #lifescience

NGS technology is synonymous with personalized therapy.

Fierce Pharma Asia—Leqembi's cost to Medicare; Takeda's $1.2B-plus Kumquat deal; Fujifilm Diosynth's reorg Medicare's spending projection on the Alzheimer's drug Leqembi is way higher than Eisai's own estimates. Takeda signed an immuno-oncology deal potentially worth more than $1.2 billion. Fujifilm Diosynth Biotechnologies is restructuring its small-scale business unit. And more. 1. Report: Spending on Leqembi could hit $3.5B next year, CMS says The Centers for Medicare & Medicaid Services estimated that Eisai and Biogen’s Leqembi would cost Medicare about $3.5 billion next year, according to a document summarizing a February stakeholder call that was first obtained by Stat. The number was much higher than Eisai's own projection of about $2 billion in revenue for 2026. 2. Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology program Takeda has signed a deal for an immuno-oncology small-molecule inhibitor from Kumquat Biosciences. Kumquat can give Takeda global development and commercialization rights after phase 1. The pact includes $130 million in near-term payments, more than $1.2 billion in future milestones, plus tiered sales-based royalties. 3. CDMO Fujifilm Diosynth's restructuring plan may leave up to 240 staffers out of work Fujifilm Diosynth Biotechnologies is laying off up to 240 workers as part of a restructuring of its small-scale business unit. The Japanese CDMO cited “the short-term impacts of reduced venture capital investment into early-stage research projects,” especially in the cell and gene therapy space, as the reason. The company’s sites in Texas, North Carolina, Massachusetts and England may be affected. 4. Shinobi strikes deal with electronics powerhouse Panasonic to create new cell therapy manufacturing platform Shinobi Therapeutics has signed a collaboration pact with Panasonic and Kyoto University to develop a new manufacturing platform to crank out induced pluripotent stem cell-based T-cell therapies more efficiently at lower costs. Panasonic is responsible for creating the closed-system manufacturing device, and Shinobi will contribute its iPSC knowledge. The first prototype is expected next April. https://lnkd.in/gzfjsyPg

🧠 Latest deals 🇺🇸🇪🇺 in life sciences and healthcare…👇 ⛵Leonard Green & Partners (LGP) and Francisco Partners have invested in RedSail Technologies to accelerate its growth and product development in pharmacy technology. 🔍 CluePoints, a Belgian provider of software for clinical trials, received a majority investment from EQT Group, with the deal expected to close in Q3 2024 - BTHT experts were involved in this process 😉 🌐 Great Point Partners acquired German drug product CDMO Lyocontract GmbH to diversify services - 📈 Simulations Plus, Inc. Plus acquired Pro-ficiency for $100 million, expanding its capabilities across drug development and doubling its market potential to $8 billion. 🏠 Addus HomeCare is set to acquire Gentiva's personal care operations for about $350 million, expanding its market in seven states and becoming Texas's largest personal care provider. 🌱 FFL Partners has invested in Apex Infusion, a provider of ambulatory infusion therapy services, to support its strategic growth initiatives. 🧩 Shore Capital Partners has announced the sale of Behavioral Innovations, a leading provider of center-based ABA therapy for children with autism, to Tenex Capital Management. 🌍 Siegfried, based in Switzerland, is acquiring an early-phase CDMO site in Wisconsin, USA, from Curia Global to expand its drug substances services. 🔬 Merck KGaA, Darmstadt, Germany is investing $66.6 million in a new quality control facility at its Darmstadt headquarters. 🏭 Kyowa Kirin International plc. plans to invest $530 million in a new biologics manufacturing facility in Sanford, North Carolina, USA. 🔬 Ipsen has extended its partnership with Marengo Therapeutics with a $1.2 billion deal to develop advanced T cell therapies for difficult-to-treat cancers. 💰 Cycle Pharmaceuticals has made a $466 million cash offer to acquire Vanda Pharmaceuticals, competing against a previous offer from Future Pak LLC. ⚛️ ITM Isotope Technologies Munich SE (ITM) has secured a $204.6 million investment led by Temasek, aimed at advancing its radiopharmaceutical pipeline. 🧬 GSK has acquired Elsie Biotechnologies for $50 million to bolster its research and development in oligonucleotide therapeutics. 👥 handl Group has acquired PSP and Osiris Health to expand its neuro rehabilitation services, aiming to bolster its health and wellbeing division. ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT is connecting senior industry experts, ex-payors and KOLs with strategy consulting firms and investors in Life Sciences and Healthcare for expert calls and senior advisory mandates. Like my content? Join 13k+ followers by clicking my name + follow + 🔔

Exciting News! 🚀🚀🚀 Healx Secures $47 Million in Series C Funding to Advance AI-Driven Rare Disease Drug Discovery Healx, an AI-enabled drug discovery platform focused on rare diseases, has successfully raised $47 million in a recent funding round. This significant financial boost is expected to propel the company's mission of accelerating the development of treatments for rare diseases, which often lack effective therapies due to limited research and investment. The infusion of funds will enable Healx to expand its AI capabilities, enhance its drug discovery processes, and ultimately bring more treatments to patients in need. 🔬 Healx leverages advanced AI algorithms to identify potential drug candidates more efficiently than traditional methods. By analyzing vast amounts of biomedical data, the platform can pinpoint existing drugs that could be repurposed for rare diseases, significantly shortening the drug discovery timeline. This innovative approach not only saves time and resources but also increases the likelihood of finding viable treatments for conditions that have been historically overlooked by the pharmaceutical industry. 🌍 With the new funding, Healx plans to broaden its collaborative efforts with patient groups, academic institutions, and pharmaceutical companies. These partnerships are crucial for gathering comprehensive data and gaining insights into the specific needs and challenges faced by patients with rare diseases. By fostering a collaborative ecosystem, Healx aims to create a more inclusive and effective drug discovery process that prioritizes patient outcomes. 💡 The investment will also support the development of Healx's internal pipeline of drug candidates. The company is committed to advancing multiple programs simultaneously, ensuring a diversified portfolio of potential treatments. This strategic approach mitigates risks and increases the chances of clinical success, ultimately benefiting the rare disease community with more therapeutic options. 📈 Healx's funding round is a testament to the growing recognition of AI's transformative potential in healthcare. Investors are increasingly acknowledging the value of AI-driven platforms in addressing unmet medical needs, particularly in the realm of rare diseases. The financial backing will not only accelerate Healx's current projects but also pave the way for future innovations in the field. 🌟 In conclusion, Healx's $47 million funding round marks a significant milestone in the journey toward revolutionizing rare disease treatment. By harnessing the power of AI and fostering collaborative partnerships, Healx is poised to make a substantial impact on the lives of patients who have long awaited effective therapies. This investment underscores the importance of innovation and collaboration in advancing healthcare for all. Source: TechCrunch #AI #DrugDiscovery #RareDiseases #HealthcareInnovation #Healx #MedicalResearch #Funding #Biotech #PatientCare #TechForGood

👨🔬 This weeks biggest news in the Life Science & Healthcare Industries ⬇ 📈 Activist investor Starboard forges $1bn stake in Pfizer to swing profits 💉 GSK reports positive findings from Phase III RSV vaccine trial 👴 Clearside Biomedical, Inc.’s wet AMD drug-device combo shines in Phase IIb study 🧠 Vanqua Bio’s Parkinson’s drug shows promise as company initiates Phase Ib study 💉 ProductLife Group boosts drug development with IntiQuan AG acquisition 🎈 Allurion Technologies’s swallowable balloon hits trial success amid weakening financials 🎗 Myriad Genetics signs five partnerships to study MRD testing in breast cancer 👨⚕️ Boehringer Ingelheim kickstarts two Phase III trials as MASH therapy wins breakthrough status 💵 Glooko win $100m investment to expand diabetes management system 👃 Aptar Pharma buys SipNose LTD’s nasal delivery technology assets ❤️ Johnson & Johnson takes over heart failure treatment company V-Wave 🤯 ShiraTronics, Inc. secures $66m in funding for implantable migraine device 🏥 Merck unveils $318m biosafety testing facility in Maryland, US 🤝 Mendaera, Inc. and EchoNous ink deal to combine robotics and ultrasound 💵 Arda Therapeutics secures $43m to develop cell depletion therapies 😷 Healgen Scientific’s dual flu and Covid-19 test receives FDA authorisation 🤝 Eli Lilly and Company and insitro team up to develop AI-powered siRNA metabolic drugs 🧬 Anima Biotech’s machine learning programme ‘reveals new mRNA drug targets' 💉 Emergent BioSolutions to donate 20,000 Narcan doses to fight opioid overdoses, CEO says 🤝 Bayer and MOMA Therapeutics partner for oncology programme 📝 DeepScribe unveils new tool to improve healthcare documentation 💻 Verbal introduces suite of AI tools designed for Zoom virtual care visits 🤝 Philips signs AI development agreement with Siloam Hospitals Group in Indonesia 👩⚕️ MSD ventures into fibroblast therapies with $1.9bn deal with Mestag Therapeutics You can keep up to date with all the top stories in the life science industry by following GlobalData Plc's healthcare industry news sites 💊 Pharmaceutical-Technology, ⚕ Medical Device Network, 💉 Clinical Trials Arena and 🏥 Hospital Management 🎯 If you would like to learn about our award winning content &marketing solution from GlobalData Marketing Solutions then please feel free to drop me a DM or send me an email - josh.jones@globaldata.com 📧 #pharma #medicaldevice #medtech #clinicaltrials #drugdevelopment #drugdelivery #vaccines #genetherapy #celltherapy #drugmanufacturing #oncology #vaccines #healthcare #lifescience

Global R&D 2024 Report: Future of Biomedical Research and Development in the Post-Pandemic Era The "Global Trends in R&D 2024" report highlights the current state and future directions of biomedical research and development in the face of the COVID-19 pandemic. Funding for R&D has increased, as has M&A activity in the biopharma sector. China is playing an increasingly important role in global R&D, particularly in the field of oncology. Clinical trial activity has decreased, with a focus on top disease areas such as oncology, immunology, metabolic/endocrinology, and neurology. The pharmaceutical industry has seen improvements in clinical development productivity, increased complexity in trials, and shifts in trial strategies. There is a growing gap between the number of drugs launched in the U.S. compared to European countries. The use of novel trial designs, real-world evidence, and artificial intelligence in drug discovery is increasing. There is a need for greater diversity in clinical trial populations and a focus on innovative trial designs and technologies to enhance productivity and efficiency. For more details please click the link! https://lnkd.in/dpk4p7w8 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Roche Holding, a global healthcare giant based in Switzerland, is renowned for its substantial contributions to the pharmaceuticals and diagnostics fields. Established in 1896 by Fritz Hoffmann, the company was born out of a vision to revolutionize healthcare, prompted by the severe impacts of illness Hoffmann witnessed. Throughout its history, Roche has shown an unwavering commitment to innovation, becoming one of the world's leading biotech firms. The company has expanded and enhanced its capabilities through strategic acquisitions and a focus on research, maintaining a strong global presence in the healthcare industry. A family-oriented ethos, initiated by Hoffmann, emphasizes integrity and collaboration, playing a pivotal role in Roche’s corporate culture. This approach has enabled a sustained focus on developing innovative therapies and diagnostic products, ensuring patients benefit from comprehensive care solutions. Roche's history is marked by significant acquisitions, such as Genentech in 2009 which bolstered its biopharmaceuticals and oncology therapy offerings, and the purchase of Ventana Medical Systems in 2008 enhancing its diagnostics division. More recent acquisitions, like Spark Therapeutics in 2019 and Foundation Medicine in 2018, highlight Roche’s strategic moves into gene therapy and personalized medicine. These acquisitions, alongside collaborations within the pharmaceutical industry, underscore Roche’s ongoing commitment to advancing healthcare science. Financially, Roche exhibits strong business outcomes without specific figures for 2022 and 2023; yet, it's clear the company continues to thrive, driven by innovative developments across its two main divisions. The Pharmaceuticals Division focuses on groundbreaking medicines, particularly in fields like oncology, immunology, and neuroscience, leveraging advanced science and biotechnology. Meanwhile, the Diagnostics Division delivers leading in-vitro diagnostics, enhancing patient care and clinical decision-making with reliable, efficient healthcare products. Roche's journey from its founding to its current status as a leader in global healthcare demonstrates a continued prioritization of medical innovation, patient care, and the advancement of health science. Through strategic growth, impactful acquisitions, and a dedication to meeting emerging health needs, Roche is shaping the future of medicine and healthcare, remaining true to its foundational vision while adapting to the evolving healthcare landscape.

In a groundbreaking advancement in the field of AI-driven drug discovery, Insilico Medicine's recent Nature Biotechnology publication introduces a promising TNIK inhibitor, INS018_055, marking the first AI-discovered and AI-designed drug to progress to Phase 2 clinical testing. This development offers a novel approach to idiopathic pulmonary fibrosis (IPF) treatment and showcases the remarkable potential of AI-driven drug discovery. This innovation is not just a milestone for drug development; it also signals a transformative shift in the pharmacy profession, underlining the expanding scope of pharmacists in the age of artificial intelligence and beyond. The role of artificial intelligence in healthcare is more crucial than ever, and this breakthrough epitomizes how AI can revolutionize our approach to complex diseases. We are particularly keen to hear thoughts from Alex Zhavoronkov, Founder and CEO of Insilico Medicine, whose visionary leadership in harnessing AI for drug discovery has brought us to the brink of this exciting frontier. His insights will undoubtedly shed light on the significance of this discovery and its implications for future healthcare innovations. At Swenson Pharmacy Advisors, our excitement about this breakthrough extends far beyond simple recognition. It echoes our dedication to championing the integration of cutting-edge technology within the healthcare landscape. This landmark achievement in AI-driven drug discovery opens up new horizons for pharmacists, showcasing the vast potential of our profession in roles that transcend traditional boundaries. It reinforces our conviction in the crucial role that pharmacists can assume in spearheading innovative solutions for healthcare challenges. As we celebrate this milestone, we remain committed to exploring and advocating for these transformative opportunities, paving the way for a future where pharmacists are at the forefront of medical innovation and patient care excellence. As we navigate this promising new era, it is clear that the intersection of pharmacy, technology, and innovative drug discovery will continue to unlock unprecedented opportunities to enhance patient care. Let us all welcome the transformative changes that lie ahead, inspired by achievements like this, as we strive to redefine the future of healthcare. #AIInHealthcare #PharmacyInnovation #DrugDiscovery #FibrosisTreatment #HealthcareFuture #InsilicoMedicine #SwensonPharmacyAdvisors